Gastroesophageal cancer: Focus on epidemiology, classification, and staging

Discovery Medicine

Volumn 16, Issue 87, 2013, Pages 103-111

  Sehdev, Amikar ^a   Catenacci, Daniel V T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATUMAXOMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOMYCIN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGODUODENOSCOPY; GASTROENTEROLOGICAL PROCEDURE; GASTROESOPHAGEAL CANCER; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HUMAN; LAPAROSCOPY; META ANALYSIS (TOPIC); PERITONEAL WASHING; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); ANIMAL; CLASSIFICATION; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; INCIDENCE; MORTALITY; PATHOLOGY; STOMACH TUMOR;

ANIMALS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 84884588859     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Springer, Tokyo, Japan, 2013.
2. Ajani J, Bentrem D, Besh S, D'amico T, Das P, Denlinger C, Fakih, MG, Fuchs CS, Gerdes H, Glasgow R, Hayman J, Hofstetter WL, Ilson D, Keswani RN, Kleinberg LR, Kom WM, Lochhart AC, Meredith K, Mulcahy MF, Orringer MB. NCCN Guidelines Version 1.2013 Panel Members Gastric Cancer. 2013. (Available online at: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf).
3. Armstrong GE. Linitis plastica. Can Med Assoc J 4(9):770-775, 1914.
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697, 2010.
5. Bar-Sela G, Hershkovitz D, Haim N, Kaidar-Person O, Shulman K, Ben-Izhak O. The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. Oncol Lett 5(2):559-563, 2013.
6. Bokemeyer CRK, Atanackovic D, Arnold D, Woell E, Büchler MW. Two-year follow-up of a phase II study on catumaxomab as part of a multimodal approach in primarily resectable gastric cancer. J Clin Oncol 30(suppl):abstr #4095, 2012.
7. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 472:467-477, 2009.
8. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 11(2):235-256, 2002.
9. Cardoso R, Coburn, N. Seevaratnam R, Sutradhar R, Lourenco LG, Mahar A, Law C, Yong E, Tinmouth J. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. In: Gastric Cancer. ppS19-S26. Sprigner, Tokyo, Japan, 2012.
10. Carr RM, Lynch JP. At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?. Gastrointest Cancer Res 2(5):253-255, 2008.
11. Catenacci DV, Cohen E, Villaflor VM. Principles of multimodality therapy. In: Gastroesophageal Tumors: Principles and Practice. Demos Medical Publishing, New York, New York, USA, 2009.
12. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Bragelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12(1):9-46, 2011.
13. Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol 27(19):e3-e4, 2009.
14. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22(12):2395-2403, 2004.
15. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the e-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 31(7):868-875, 2013.
16. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83(10):2049-2053, 1998.
17. DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg A. Principles and Practice of Oncology. Ninth, North American Edition. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA, 2011.
18. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241(1):27-39, 2005.
19. Dikken JL, Van De Velde CJ, Gonen M, Verheij M, Brennan MF, Coit DG. The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol 19(8):2443-2451, 2012.
20. Edge SBB, Compton CC, Fritz AG, Greene FL, Trotti A. (Eds.). AJCC Cancer Staging Handbook, Springer, New York, New York, USA, 2009.
21. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 15(4):751-764, 2006.
22. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 21(3):258-270, 2003.
23. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47(7):436-444, 2010.
24. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151(2):121-128, 2009.
25. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24(7):1754-1761, 2013.
26. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523-1529, 2008.
27. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29(36): 4789-4795, 2011.
28. Hasegawa S, Yoshikawa T, Aoyama T, Hayashi T, Yamada T, Tsuchida K, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol 20(3):773-779, 2013.
29. Hernandez-Ramirez RU, Galvan-Portillo MV, Ward MH, Agudo A, Gonzalez CA, Onate-Ocana LF, Herrera-Goepfert R, Palma-Coca O, Lopez-Carrillo L. Dietary intake of polyphenols, nitrate and nitrite and gastric cancer risk in Mexico City. Int J Cancer 125(6):1424-1430, 2009.
30. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science 306(5701):1568-1571, 2004.
31. Hunerbein M, Ghadimi BM, Haensch W, Schlag PM. Transendoscopic ultrasound of esophageal and gastric cancer using miniaturized ultrasound catheter probes. Gastrointest Endosc 48(4):371-375, 1998.
32. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 61(2):69-90, 2011.
33. Kangelaris KN, Gruber SB. Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. JAMA 297(21):2410-2411, 2007.
34. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21(19):3647-3650, 2003.
35. Kaurah P, Huntsman DG. Hereditary diffuse gastric cancer. In: GeneReviews. RA Pagon, TD Bird, CR Dolan, K Stephens, MP Adam (Eds.). University of Washington Press, Seattle, Washington, USA, 1993.
36. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56(1):1-9, 2003.
37. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49, 1965.
38. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107(2):325-333, 2012.
39. Lerut T. Carcinoma of the Esophagus and Gastro-esophageal Junction. W. Zuckschwerdt Verlag GmbH, Munich, Germany, 2001.
40. Li HC, Stoicov C, Rogers AB, Houghton J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J Gastroenterol 12(3):363-371, 2006.
41. Lordick F, Kang, YK, Salman P, Oh SC, Bodoky G, Kurteva GP, Volovat CD, Moiseyenko V, Sawaki A, Park JO, Gorbunova VA, Goette H, Melezinkova H, Stroh C, Moehler M. Clinical outcome according to HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 31(suppl):abstr #4021, 2013.
42. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, Rohren E, Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 7(6):422-430, 2005.
43. Marsman WA, Tytgat GN, Ten Kate FJ, Van Lanschot JJ. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol 92(3):160-168, 2005.
44. Mcghan LJ, Pockaj BA, Gray RJ, Bagaria SP, Wasif N. Validation of the updated 7th edition AJCC TNM staging criteria for gastric adenocarcinoma. J Gastrointest Surg 16(1):53-61; discussion 61, 2012.
45. Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 17(12):3173-3180, 2010.
46. Nath J, Moorthy K, Taniere P, Hallissey M, Alderson D. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 95(6):721-726, 2008.
47. Navarro Silvera SA, Mayne ST, Risch HA, Gammon MD, Vaughan T, Chow WH, Dubin JA, Dubrow R, Schoenberg J, Stanford JL, West AB, Rotterdam H, Blot WJ. Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol 21(7):543-550, 2011.
48. Nissan A, Garofalo A, Esquivel J. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: why haven't we reached the promised land?. J Surg Oncol 102(5):359-360, 2010.
49. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243(1):74-81, 2006.
50. Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 24(5):1253-1261, 2013.
51. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 28(suppl):abstr #4005, 2012.
52. Peeters KC, Kattan MW, Hartgrink HH, Kranenbarg EK, Karpeh MS, Brennan MF, Van De Velde CJ. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 103(4):702-707, 2005.
53. Polk DB, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10(6):403-414, 2010.
54. Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 1(3):145-165, 2009.
55. Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 14(10):1479-1490, 2008.
56. Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, Asfaha S, Dubeykovskaya Z, Mahmood U, Figueiredo JL, Kitajewski J, Shawber C, Lightdale CJ, Rustgi AK, Wang TC. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer cell 21(1):36-51, 2012.
57. Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10(8):954-960, 2003.
58. Richards FM, Mckee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, Mckeown C, Sanders DS, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8(4):607-610, 1999.
59. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232(3):353-361, 2000.
60. Samee A, Moorthy K, Jaipersad T, Crisp W, Cheruvu C, Elder J, Deakin M. Evaluation of the role of laparoscopic ultrasonography in the staging of oesophagogastric cancers. Surg Endosc 23(9):2061-2065, 2009.
61. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29, 2012.
62. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85(11):1457-1459, 1998.
63. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30(2):288-295, 2003.
64. Stalsberg H, Taksdal S. Stomach cancer following gastric surgery for benign conditions. Lancet 2(7735):1175-1177, 1971.
65. Steevens J, Schouten LJ, Goldbohm RA, Van Den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut 59(1):39-48, 2010.
66. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, Coit DG, Brennan MF. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 251(4):640-646, 2010.
67. Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. J Clin Oncol 30(28):3493-3498, 2012.
68. Talsma K, Van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, Van Lanschot JJ, Wijnhoven BP. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol 19(7):2142-2148, 2012.
69. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 123(6):1422-1428, 2008.
70. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10(2):75-83, 2007.
71. Van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98(3):547-557, 2008.
72. Varon C, Dubus P, Mazurier F, Asencio C, Chambonnier L, Ferrand J, Giese A, Senant-Dugot N, Carlotti M, Megraud F. Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology 142(2):281-291, 2012.
73. Volk J, Parsonnet J. Epidemiology of Gastric Cancer and Helicobacter pylori. Springer Science + Business Media LLC, New York, New York, USA, 2009.
74. Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R, Vincent M, Lu X, Bellizzi AM, Ho KY, Crum CP, Xian W, Mckeon F. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 145(7):1023-1035, 2011.
75. Webb PM. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49(3):347-353, 2001.
76. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058-3065, 2001.
77. Werner M, Becker KF, Keller G, Hofler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 127(4):207-216, 2001.
78. Westerterp M, Van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, Van Lanschot JJ, Sloof GW. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236(3):841-851, 2005.
79. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14(10):2702-2713, 2007.